Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: an overview of reviews
Citation:
Andrew Dullea, Lydia O'Sullivan, Marie Carrigan, Susan Ahern, Maeve McGarry, Kirsty O'Brien, Patricia Harrington, Kieran A. Walsh, Susan M. Smith, M�ir�n Ryan, Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: an overview of reviews, Seminars in Nuclear Medicine, 2024Download Item:
Abstract:
The aim of this overview was to consolidate existing evidence syntheses and provide a comprehensive overview of the evidence for 18F-prostate specific membrane antigen (PSMA)
PET/CT in the staging of high-risk prostate cancer and restaging after biochemical recurrence. An overview of reviews was performed and reported in line with the preferred reporting items for overview of reviews (PRIOR) statement and synthesis without meta-analysis
(SWiM) reporting guidelines. A comprehensive database and grey literature search were
conducted up to July 18, 2023. Systematic reviews were assessed using the risk of bias in
systematic reviews (ROBIS) tool. The certainty of the evidence was assessed using grading
of recommendations, assessment, development and evaluations (GRADE). 11 systematic
reviews were identified; 10 were at high or unclear risk of bias. Evidence reported on a perpatient, per-lymph node, and per-lesion basis for sensitivity, specificity and overall accuracy was identified. There was a lack of data on dose, adverse events and evidence directly
comparing 18F-PSMA PET/CT to other imaging modalities. Evidence with moderate to very
low certainty indicated high sensitivity, specificity and accuracy of 18F-PSMA PET/CT in
patients with high-risk prostate cancer and biochemical recurrence. There was considerably lower certainty evidence and greater variability in effect estimates for outcomes for the
combined intermediate/high-risk cohort. While evidence gaps remain for some outcomes,
and most systematic reviews were at high or unclear risk of bias, the current evidence base
is broadly supportive of 18F-PSMA PET/CT imaging in the staging and restaging of patients
with high-risk prostate cancer and biochemical recurrence.
Author's Homepage:
http://people.tcd.ie/dulleaahttp://people.tcd.ie/susmith
Description:
PUBLISHED
Author: Dullea, Andrew
Advisor:
Smith, SusanPublisher:
Seminars in Nuclear MedicineType of material:
Journal ArticleSeries/Report no:
Seminars in Nuclear Medicine;Availability:
Full text availableKeywords:
Systematic Review, prostatic neoplasms, PSMA, Positron Emission Tomography Computed Tomography, PET/CTSubject (TCD):
Cancer , CANCER , Evidence Synthesis , Evidence based practice , HEALTH SERVICES RESEARCH , Medicine , RADIOLOGY , Radiology, tomography and medical imagingISSN:
0001-29980001-2998
Metadata
Show full item recordLicences: